NAVLE Nervous

Canine Granulomatous Meningoencephalitis (GME) Study Guide

📅 March 28, 2026 ⏱ 25 min read

Granulomatous meningoencephalomyelitis (GME) is an idiopathic, non-suppurative inflammatory disease of the central nervous system (CNS) in dogs.

Overview and Clinical Importance

Granulomatous meningoencephalomyelitis (GME) is an idiopathic, non-suppurative inflammatory disease of the central nervous system (CNS) in dogs. It is characterized by perivascular accumulation of mononuclear cells (primarily macrophages and lymphocytes) forming granulomatous lesions within the brain and/or spinal cord. GME is the second most common inflammatory CNS disease in dogs after canine distemper virus encephalitis, accounting for 5-25% of all CNS disorders.

The disease predominantly affects young to middle-aged (4-8 years), small breed dogs, with a potential female predisposition. The etiology remains unknown, though an immune-mediated pathogenesis is strongly suspected. Without treatment, GME is typically progressive and fatal.

High-YieldOn the NAVLE, when you see a young to middle-aged, small breed dog (especially Poodles or Terriers) presenting with acute, progressive, multifocal neurologic signs and mononuclear pleocytosis on CSF analysis, GME should be at the top of your differential list. Remember: definitive diagnosis requires histopathology, but presumptive diagnosis is commonly made based on signalment, clinical signs, MRI, and CSF findings after excluding infectious causes.

Parameter	Characteristics
Age	4-8 years (young to middle-aged); can occur at any age
Sex	Possible female predisposition reported in some studies
Breed	Small and toy breeds overrepresented; can affect any breed

Etiology and Pathogenesis

The exact etiology of GME remains unknown (idiopathic). However, several pathogenic mechanisms have been proposed:

Proposed Mechanisms

Immune-mediated/Autoimmune: The most widely accepted theory. Inflammatory infiltrates consist predominantly of CD3+ T lymphocytes and activated macrophages with MHC II expression, suggesting a delayed-type hypersensitivity (DTH) reaction against CNS antigens.
Aberrant response to infectious agents: Some researchers suggest GME may represent an abnormal immune response to an unidentified infectious agent. Studies have searched for viral DNA (canine herpesvirus, adenovirus, parvovirus) but no association has been proven.
Post-vaccination reaction: The increased recognition of GME coinciding with declining distemper cases has led some to hypothesize a modified immune response after vaccination, though this remains unproven.
Genetic predisposition: Breed predilections suggest a hereditary component, though specific genetic markers have not been identified for GME (unlike NME in Pugs and Maltese).

NAVLE TipGME is classified under Meningoencephalitis of Unknown Origin (MUO) when histopathologic confirmation is unavailable. MUO encompasses GME, necrotizing meningoencephalitis (NME), and necrotizing leukoencephalitis (NLE). All are treated similarly with immunosuppressive therapy.

Form	Characteristics	Clinical Signs
Focal	Space-occupying granulomatous mass Most common in cerebrum or brainstem Slower onset (3-6 months) Better prognosis	Signs reflect lesion location Seizures, behavior changes (forebrain) Vestibular signs, cranial nerve deficits (brainstem)
Disseminated (Multifocal)	Diffuse lesions throughout CNS Most common form Acute, rapid progression (2-6 weeks) Poorer prognosis	Multifocal neurologic deficits Cervical hyperesthesia common Ataxia, paresis, vestibular signs Altered mentation, seizures
Ocular	Optic nerve involvement Uncommon form Extension of CNS disease Usually bilateral	Acute blindness Dilated, unresponsive pupils Optic neuritis on fundoscopy May progress to uveitis, glaucoma

Signalment and Breed Predispositions

Typical Signalment

Predisposed Breeds

Poodles (Toy, Miniature)
Terrier breeds (especially small terriers)
Chihuahuas
Maltese
Dachshunds
Cocker Spaniels

High-YieldUnlike NME (Pug dog encephalitis) and NLE (Yorkie encephalitis), GME does not have strict breed-specific predilections and can affect any breed. However, small breeds are significantly overrepresented.

Location	Associated Clinical Signs
Forebrain (Cerebrum)	Seizures, behavior changes, circling, head pressing, vision deficits, contralateral proprioceptive deficits
Brainstem	Central vestibular signs (head tilt, nystagmus, ataxia), cranial nerve deficits (V, VII, VIII), altered mentation, tetraparesis
Cerebellum	Cerebellar ataxia (hypermetria, intention tremor), broad-based stance, menace deficits with intact PLR
Spinal Cord	Cervical hyperesthesia (common), paresis/paralysis, UMN or LMN signs depending on level
Optic Nerves	Acute blindness, dilated pupils, absent PLR, papilledema or optic disc swelling

Clinical Forms and Presentation

GME is classified into three clinical forms based on lesion distribution and presenting signs:

Common Clinical Signs by Neuroanatomic Location

Exam Focus: The most commonly reported clinical signs on the NAVLE include: seizures, vestibular deficits, ataxia, paresis, cervical pain/hyperesthesia, and behavioral changes. When you see multifocal neurologic signs with rapid progression in a small breed dog, think GME!

Parameter	Normal Values	GME Findings
Total Nucleated Cell Count (TNCC)	Less than 5 cells/microL	Elevated (typically 50-900 cells/microL); marked pleocytosis common
Cell Type	Rare lymphocytes	Mononuclear pleocytosis (lymphocytes predominate, with monocytes/macrophages); may be mixed
Protein	Less than 25-30 mg/dL	Elevated (often markedly); predominantly globulin
Appearance	Clear, colorless	May be turbid if TNCC greater than 500/microL

Diagnostic Approach

Definitive diagnosis of GME requires histopathological examination of CNS tissue (brain biopsy or necropsy). However, a presumptive diagnosis is commonly made based on:

Initial Workup

Complete Blood Count (CBC): Usually normal; may show stress leukogram or neutrophilia
Serum Chemistry: Typically normal; rule out metabolic causes of neurologic signs
Thoracic Radiographs: Rule out metastatic disease or systemic illness
Infectious Disease Testing: CRITICAL to rule out Toxoplasma, Neospora, Cryptococcus, canine distemper virus, tick-borne diseases (geographic considerations)

Cerebrospinal Fluid (CSF) Analysis

CSF analysis is a cornerstone of GME diagnosis. Classic findings include:

High-YieldUp to 10% of dogs with GME may have NORMAL CSF! A normal CSF does not rule out GME, especially if corticosteroids have been administered prior to collection (up to 6 weeks).

Magnetic Resonance Imaging (MRI)

MRI is the imaging modality of choice for CNS inflammatory disease. GME lesions have variable and non-specific MRI characteristics:

T2-weighted and FLAIR: Hyperintense lesions (bright)
T1-weighted: Iso- to hypointense lesions
Post-contrast T1: Variable enhancement (none to marked); ring enhancement possible in focal form
Distribution: Predominantly white matter; may be focal (single mass) or multifocal
Common locations: Brainstem, cerebellum, cervical spinal cord, cerebrum
Mass effect: May be present in focal form; ill-defined margins typical

NAVLE TipMRI alone cannot definitively distinguish GME from brain tumors (gliomas) or other inflammatory diseases. Focal GME can mimic a glioma on MRI! The combination of signalment, clinical presentation, CSF analysis, and negative infectious disease testing is essential for presumptive diagnosis.

Category	Differentials
Other MUO Subtypes	Necrotizing meningoencephalitis (NME) - Pugs, Maltese, Chihuahuas; Necrotizing leukoencephalitis (NLE) - Yorkshire Terriers, French Bulldogs
Viral Infections	Canine distemper virus (CDV) encephalitis, Rabies
Protozoal Infections	Toxoplasma gondii, Neospora caninum
Fungal Infections	Cryptococcus neoformans, Blastomyces dermatitidis, Coccidioides immitis (geographic)
Tick-borne Diseases	Ehrlichia canis, Anaplasma phagocytophilum, Rocky Mountain spotted fever
Neoplasia	Glioma (astrocytoma, oligodendroglioma), Lymphoma, Histiocytic sarcoma, Meningioma
Other Inflammatory	Steroid-responsive meningitis-arteritis (SRMA), Eosinophilic meningoencephalitis
Vascular	Ischemic stroke, Hemorrhagic stroke

Histopathology (Definitive Diagnosis)

Definitive diagnosis requires histopathological examination. The hallmark lesions of GME include:

Perivascular cuffing: Dense accumulations of mononuclear inflammatory cells (lymphocytes, macrophages, plasma cells) around blood vessels in characteristic 'whorling' patterns
Granulomatous inflammation: Nodular aggregates of epithelioid macrophages forming granulomas; may contain multinucleated giant cells
White matter predilection: Lesions occur predominantly in CNS white matter (cerebrum, cerebellum, brainstem, spinal cord)
Non-suppurative meningitis: Mononuclear infiltration of meninges
Angiocentric distribution: Lesions characteristically oriented around blood vessels

Drug	Dosage	Mechanism	Monitoring
Cytosine Arabinoside (Cytosar)	50 mg/m2 SQ BID for 2 days, repeat every 3-6 weeks	Antimetabolite; crosses BBB; inhibits DNA synthesis	CBC 10-14 days post-treatment (myelosuppression)
Cyclosporine	5-12 mg/kg PO q12-24h	Calcineurin inhibitor; inhibits T-cell activation	Trough levels (target 200-400 ng/mL); CBC, chemistry
Mycophenolate Mofetil (MMF)	10-20 mg/kg PO q12h	Inhibits purine synthesis; affects T and B cells	CBC, GI side effects common
Leflunomide	4-6 mg/kg PO q24h	Pyrimidine synthesis inhibitor	CBC, chemistry regularly
Procarbazine	25-50 mg/m2 PO daily	MAO inhibitor; alkylates DNA; crosses BBB	CBC weekly initially (myelosuppression)

Differential Diagnosis

The differential diagnosis for GME includes other causes of focal or multifocal CNS disease:

High-YieldALWAYS rule out infectious causes before initiating immunosuppressive therapy! Immunosuppression in the face of an undiagnosed infection can be fatal. Test for Toxoplasma, Neospora, Cryptococcus, and regional pathogens based on geographic history.

Better Prognosis	Worse Prognosis
Focal form (vs. disseminated) Forebrain localization Early treatment (less than 7 days of signs) Younger dogs Improvement within first month Clean MRI at 3 months Two or more immunosuppressive drugs Radiation therapy (focal form)	Disseminated/multifocal form Brainstem/caudal fossa involvement Seizures at presentation Altered mentation/obtundation No response within first 3 months Rapid progression Corticosteroid monotherapy

Treatment

Treatment of GME is directed at immunosuppression to control the inflammatory response. GME is not curable; treatment aims to induce and maintain remission. Most dogs require lifelong therapy.

First-Line: Corticosteroids

Prednisone/Prednisolone remains the cornerstone of GME therapy:

Initial immunosuppressive dose: 1-2 mg/kg PO BID for 2-4 weeks
Gradual taper: Reduce dose by 25% every 4 weeks once clinical signs stabilize
Maintenance goal: Lowest effective dose, ideally alternate-day therapy (0.5 mg/kg every other day)
Side effects: PU/PD, polyphagia, weight gain, hepatomegaly, GI ulceration, iatrogenic hyperadrenocorticism

Second-Line Immunosuppressive Agents

Secondary agents are commonly added to reduce corticosteroid dose and improve outcomes:

Radiation Therapy

Radiation therapy may provide the longest survival times for focal GME. Studies report median survival times greater than 400 days with radiation therapy compared to 41 days with corticosteroids alone for focal forebrain GME.

Exam Focus: On the NAVLE, know that corticosteroids are first-line treatment, cytosine arabinoside and cyclosporine are commonly used second-line agents, and radiation therapy offers the best outcomes for focal GME. Treatment is lifelong and relapses are common.

Prognosis

Prognosis for GME is generally guarded to poor, though variable based on several factors:

Median Survival Times

Focal GME (corticosteroids alone): 114 days (range: 3-6 months)
Disseminated GME (corticosteroids alone): 8 days (often less than 6 weeks)
Focal GME (radiation therapy): Greater than 400 days (up to greater than 1,200 days reported)
Combination immunosuppressive therapy: Variable; 570-1,035 days reported in some studies
Overall range: 14-1,063+ days post-diagnosis

High-Yield15-25% of dogs with GME die or are euthanized within the first week of diagnosis. However, dogs that survive the first month have a reasonable chance of living months to over a year with appropriate therapy.

Memory Aids for the NAVLE

GME = "Granulomas Making Encephalitis"

Granulomatous inflammation (perivascular cuffs of macrophages and lymphocytes)

Mononuclear pleocytosis on CSF (lymphocytes predominate)

Exclude infections first, then treat with immunosuppression

"SMALL Dogs Get GME"

Small breeds (Poodles, Terriers, Chihuahuas)

Middle-aged (4-8 years)

Acute onset, progressive course

Lymphocytes elevated in CSF

Lifelong immunosuppression needed

"3 Forms of GME" = F.O.D.

Focal (single mass, slower progression, better prognosis)

Ocular (optic neuritis, acute blindness)

Disseminated (multifocal, rapid progression, worst prognosis)

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →